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combination over the free combination of BDP CFC
pMDI and FF DPIDear editor,
I read with surprise the article by Huchon et al.1 where
an extra-fine HFA combination of beclomethsaone
dipropionate (BDP) and formoterol fumarate (FF) given
via a single pressurised metered-dose inhaler (pMDI) was
compared with BDP CFC pMDI and FF dry powder inhaler
(DPI) given via separate inhalers. The authors suggest
that ‘‘the synergistic effect of the two drug classes at
various cellular types in the lungs can be enhanced
through their co-administration and consequent co-
deposition, which may be favoured by the extra-fine
formulation of the BDP/FF combination’’. Firstly, I would
like to clarify that the synergistic effect obtained thanks
to co-deposition is not necessarily the reason for this
superior efficacy. From my point of view, the superior
efficacy of the fixed combination is due to the BDP
component since the FF component is known to be
equivalent.2e5 In contrast, the BDP component shows
higher efficacy when the distribution is more homoge-
neous within the lungs compared to the central deposi-
tion produced by the CFC reference product.6 The
superiority of the BDP component and the equivalence of
the FF component can be easily deduced based on
pharmacokinetic (PK) data. A PK crossover study in 12
healthy volunteers2 showed a larger lung deposition and
more homogeneous or peripheral distribution even after
the dose reduction (1:2.5) that has been used to develop
this fixed combination. Similarly, its superior safety
profile is due to its lower total systemic exposure. The
detection of this lung deposition superiority by means of
the insensitive clinical variables is possible thanks to the
large magnitude of the difference caused by the poor
peripheral deposition of the CFC reference product.
However, as the difference with respect to the freeDOI of original article: 10.1016/j.rmed.2008.09.002.
0954-6111/$ - see front matter ª 2009 Elsevier Ltd. All rights reserved
doi:10.1016/j.rmed.2009.03.025combination is smaller in the other combination
products, it is more difficult to show this difference with
clinical variables. Secondly, and more importantly,
although the authors did not claim it directly, I would like
to clarify that the co-deposition or improved deposition
is not exclusive of fixed combination products, as some
would like to make believe because the patent
protection is longer for the combination products of BDP/
FF, budesonide/FF and fluticasone propionate/salme-
terol. From my point of view, an equivalent effect would
be obtained with the free combination of equivalent HFA
BDP and HFA FF or FF DPI products.
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